Additional in vivo experiments are required to evaluate whether blocking β-cell NF-κB activation will indeed protect these cells against the immune response, which would lead to β-cell death in islets transplanted in animal models of type 1 diabetes. Here, NFKB1 is linked to type 1 diabetes mellitus.